Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94044 | 0.89 | AR (0.50) | AR | |
| SCHEMBL10088427 | 0.86 | AR (0.47) | AR | |
| SCHEMBL94947 | 0.73 | AR (0.36) | AR | |
| SCHEMBL159928 | 0.73 | AR (0.40) | AR | |
| Vk5211 SCHEMBL29362482 | 0.71 | AR (1.00) | AR | |
| Vk5211 SCHEMBL220947 | 0.71 | AR (1.00) | AR | |
| Vk5211 SCHEMBL222508 | 0.71 | AR (1.00) | AR | |
| Vk5211 SCHEMBL14837444 | 0.71 | AR (1.00) | AR | |
| Vk5211 SCHEMBL221160 | 0.71 | AR (1.00) | AR | |
| Vk5211 SCHEMBL221159 | 0.71 | AR (1.00) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | claimed |
| EP-2426117-A1 | THIOPHENE DERIVATIVE | Sumitomo Chemical Company, Limited (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065231-A1 | THIOPHENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-2426117-A1 | THIOPHENE DERIVATIVE | Sumitomo Chemical Company, Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065231-A1 | THIOPHENE DERIVATIVE | AR, NR5A1, SHBG | AR 1/4885KDM4E 2227/4885MEN1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.